A 69-year-old man was referred to our hospital for further evaluation of an abdominal mass. After admission, he was suspected of having a malignant mesenteric tumor. Laboratory data disclosed thrombocytopenia with increased levels of platelet-associated immunoglobulin G. On surgery, the tumor involved the ileal mesentery, invading the urinary bladder and mucosal surface of the terminal ileum. The diagnosis of mesenteric lymphoma with immune throm bocytopenia was made. Complete remission was obtained after surgery and the subsequent three courses of combination chemotherapy. However, thrombocytopenia still persisted. This rare presentation is discussed with a review of the available literature.
Introduction
Malignant lymphoma refers to a general term for non-epithelial malignant tumor originating from lymphatic tissues; it rarely occurs in the mesentery. Immune thrombocytopenia may occur in lymphoproliferative diseases such as chronic lymphocytic leukemia (1), but it is distinctly rare in patients with malignant lymphoma. In this paper, we present a patient with non-Hodgkin malignant lymphoma in the mesentery who also displayed immune thrombocytopenia. The implication of the relationship between malignant lymphoma and immune thrombocytopenia is discussed with a review of the available literature.
Case Report
A 69-year-old man was referred to our hospital for further evaluation of a palpable right lower quadrant abdominal mass on August 28, 1990. He had undergone an operation for aneurysm of the abdominal aorta 8 years earlier, at which time the thrombocyte number was normal, ranging from 12.5-27.3 x 104/mm3. On admission, blood pressure was 140/94 mmHg. No superficial lymph nodes were palpable. There was no petechial purpura over the skin. The lungs and heart were normal. A solid mass, measuring 8 X 6cm, was palpated in the lower right quadrant of the abdomen. However, the liver, spleen and kidneys were not palpable. Laboratory studies disclosed the following: The red blood cell count was 467 X 104/mm3, hematocrit 40.1% and hemoglobin 12.9g/dl. The white blood cell count was 14,800/mm3 with 37% polymorphonuclear leukocytes, 18% lympho cytes and 44% monocytes. The platelet count was 5.6 x 104/mm3. Prothrombin time and plasma fibrinogen were normal. The blood sedimentation rate was 9mm/hour and C-reactive protein was 2.4mg/dl. The serum total protein was 7.6g/dl with an albumin concentration of 4.0g/dl. Renal and hepatic function tests as well as serum electrolytes were normal. Serum immunoglobulin levels were normal. Platelet-associated immunoglobulin G (PA-IgG) was positive with a maximum level of 183.7ng/107 platelet (normal <25ng/107 platelet).
Coombs' test was negative. The urine was normal. M-CSF (colony stimulating factor) and GM-CSF were below the detection limit. Terminal ileum and a part of ascending colon were displaced by the mass, but the mucosal surface and wall of the intestine were smooth on barium enema study ( Fig. 1) . Ultrasonography revealed an oblong, slightly lobulated sonolucent solid mass, measuring 9 x 6 x 7cm with a central area of increased echogenecity (Fig. 2) . A CT scan demonstrated a plaque like, solid mass enveloping the mesenteric fat (Fig. 3) . There was no evidence of periaortic or retroperitoneal adenopathy. The result of drip infusion pyelography (DIP) was not remarkable. On superior mesenteric arteriography, the tumor was hypovascular and the arteries were distended with smooth encasement in the periphery (Fig. 4) . A 67Ga citrate radionuclide scan showed the uptake of gallium citrate in the lower mid abdomen, coincident with the site of the tumor (Fig. 5 ). Foot lymphography gave normal results. On surgery, the tumor was located in the mesentery surrounded by the cecum and terminal ileum, measuring 13 x 10 cm; part ofthe tumor invaded the urinary bladder and mucosal surface of the terminal ileum, forming an ulcer (Fig. 6 ). The tumor was resected completely with partial ileotomy. Splenectomy was not performed because the spleen appeared normal. The cut surface of the resected specimen was mostly white, and partly yellowish with hemorrhagic spots. Microscopically, the tumor cells with a large nucleus proliferated invasively, destroying the normal follicular structure (Fig. 7) . The diagnosis of mesenteric lymphoma is often dif ficult, but with the development of CT scan and ultraso nography, the detection of such tumors is expected to increase. The encasement of the superior mesenteric artery and fat tissue by tumor infiltrating the mesenteric leaves on CT scan or ultrasonography is a characteristic appearance in mesenteric lymphoma and it is often called the "sandwich sign" (6) . In the present case, the encasement of fat tissue by the tumor was identified. However, the superior mesenteric artery was not clearly demonstrated within it. On angiography, mesenteric lymphoma often appears either hypovascular (as with the present case) or avascular, but may sometimes be hypervascular with diffuse staining during the capillary phase (7). Another characteristic feature of the present case is thrombocytopenia. Thrombocytopenia is a common complication of advanced lymphoproliferative disease. It is often presumed to be due to marrow infiltration or chemo-radiotherapy and less commonly due to hyper splenism, (8-10) while it may be ascribed to the dis turbances of immune function present in patients with malignant lymphoma (ll) . These patients often present with several autoantibodies such as to red cells, neutro phils and to thrombocytes. The present case had an adequate number of megakaryocytes and no evidence of tumor cell infiltration in the bone marrow, small spleen, or other illnesses associated with immune throm bocytopenia. Further, the thrombocyte count was in versely correlated with the level of PA-IgG (r = -0.97, p <0.01, n = 6) (Fig. 8, inset ) in addition to the presence of thrombocytopenia before chemotherapy. These findings support the notion that immune destruction due to an elevated level of PA-IgG could be the cause of thrombocytopenia in the present case. According to Berkman et al (12) , PA-IgG is usually elevated in patients with lymphoma (39% in Hodgkin's disease and 20% in non-Hodgkin's lymphoma), but its concentration is not always related to the presence of thrombocytopenia. Immune thrombocytopenic purpura was observed only in 1% (13) and 0.4% (14) in a large series of patients with Hodgkin's disease and non-Hodgkin lymphoma, respectively. Therefore, the incidence of immune thrombocytopenia is distinctly rare in patients with malignant lymphoma. Fink and Al-Mondhiry (15) reviewed 17 patients with idiopathic thrombocytopenic purpura (ITP) associated with malignant lymphoma and reported that ITP was coincidental with the diagnosis of malignant lymphoma in 6 (35%), but in 9 patients (53%), ITP developed several months after the diagnosis of malignant lymphoma had been established, while in the remaining 2 (12%), ITP heralded the onset of lymphoma. In the present case, the thrombocyte count was normal 8 years pre viously, but the thrombocyte count just prior to the onset of lymphoma was not available and therefore, we could not determine the exact relationship between the emergence of immune thrombocytopenia and malig nant lymphoma.
It is reported that ITP may be encountered in all stages and histological subtypes of Hodgkin's disease (13) . In contrast, the extent of non-Hodgkin lymphoma by stage and histopathologic type at the time of immune thrombocytopenia has not been previously explored in detail. It is known that herpes zoster or other viral infections may induce immune thrombocytopenic purpura (13) and the possibility of cytomegalovirus inducing throm bocytopenia in Hodgkin's disease has been discussed (16) . However, in the present case, there was no definite evidence suggestive of such viral infections. The occurrence of immune thrombocytopenic purpura seems to correlate with the activity of the underlying lymphoma (15) and it has also been reported that PA IgG may be a useful marker for disease activity in patients with advanced Hodgkin's disease (16) , suggesting that PA-IgG is produced by the tumor. In the present case, the origin of PA-IgG and the significance of PA-IgG as a disease marker are not clear, especially considering the fact that normalization of the thrombocyte count and PA-IgG level did not occur in spite of the successful control of the underlying lymphoma by operation and subsequent chemotherapy (Fig. 8 ).
In conclusion, the association between immune thrombocytopenia and malignant lymphoma (especially non-Hodgkin type) is unclear in many aspects and remains to be clarified by further study with more extensive cases including the present case.
This case was presented at the 135th Annual Meeting of Internal Medicine of Kinki District held in Kyoto on Sept. 14, 1991.
